Growth & profitability
- Revenue has grown 8.4% per year over the past 5 years.
DNTH Financials Dianthus Therapeutics, Inc. /De/
10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$162M | 0.0% | -8739.3% | — | — | $51M |
| 2024 | $6M | -$85M | 0.0% | -1633.7% | — | — | $23M |
| 2023 | $3M | -$44M | 0.0% | -1704.7% | — | — | $132M |
| 2022 | $6M | -$28M | 0.0% | -462.9% | -$29M | — | $15M |
| 2021 | $1M | -$13M | 0.0% | -886.6% | -$11M | — | $8M |
| 2020 | — | -$75M | — | — | -$64M | — | $58M |
| 2019 | — | -$77M | — | — | -$60M | — | $65M |
| 2018 | — | -$58M | — | — | -$50M | — | $58M |
| 2017 | — | -$35M | — | — | -$24M | — | $51M |
| 2016 | — | -$9M | — | — | -$7M | — | $5M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$41M | — | — | — | — | $628M |
| Dec '25 | $284000 | -$64M | 0.0% | -24486.3% | — | — | $51M |
| Sep '25 | $396000 | -$37M | 0.0% | -10173.7% | — | — | $56M |
| Jun '25 | $193000 | -$32M | 0.0% | -18096.9% | — | — | $13M |
| Mar '25 | $1M | -$30M | 0.0% | -2852.7% | — | — | $10M |
| Dec '24 | $1M | -$28M | 0.0% | -2406.9% | — | — | $23M |
| Sep '24 | $2M | -$25M | 0.0% | -1376.6% | — | — | $34M |
| Jun '24 | $2M | -$18M | 0.0% | -1191.8% | — | — | $314M |
| Mar '24 | $874000 | -$14M | 0.0% | -2041.6% | — | — | $330M |
| Dec '23 | — | -$11M | — | — | — | — | $132M |
| Sep '23 | $924000 | -$15M | 0.0% | -1705.5% | — | — | $157M |
| Jun '23 | — | -$11M | — | — | -$5M | — | $40M |
| Mar '23 | — | -$7M | — | — | -$11M | — | $23M |
| Dec '22 | — | -$58M | — | — | -$9M | — | $15M |
| Sep '22 | $1M | -$8M | 0.0% | -703.7% | $16M | — | $37M |
| Jun '22 | — | -$6M | — | — | -$17M | — | $55M |
| Mar '22 | — | -$23M | — | — | -$20M | — | $72M |
| Dec '21 | — | -$19M | — | — | -$16M | — | $8M |
| Sep '21 | — | -$17M | — | — | -$15M | — | $158M |
| Jun '21 | — | -$17M | — | — | -$13M | — | $155M |
Valuation over time
How the market has priced DNTH against its own fundamentals since 2023-09 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 117.0× (Sep '23) to 2459.6× (Jun '26).
P/S
Frequently asked questions
Is DNTH growing its revenue and profit?
Over the past 5 years, Dianthus Therapeutics, Inc. /De/'s revenue has grown 8.4% per year. These are computed facts, not advice.
How much debt does DNTH have?
As of FY2025, Dianthus Therapeutics, Inc. /De/ reported — of total debt against $51M of cash.
What is DNTH's profit margin?
In FY2025, gross margin was —, operating margin -8739.3%, and net margin -7973.3%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.